<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Angelis Consulting Group | Nymand | Activity</title>
	<link>https://angelisconsulting.com/members/pathshade95/activity/</link>
	<atom:link href="https://angelisconsulting.com/members/pathshade95/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Nymand.</description>
	<lastBuildDate>Mon, 17 Aug 2026 04:31:04 -0500</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">974510c4e045e475da9efd161d4c52a4</guid>
				<title>Nymand posted an update: Multiple Myeloma Class Action Lawsuit: What Patients Need to [&#133;]</title>
				<link>https://angelisconsulting.com/activity/p/19662/</link>
				<pubDate>Mon, 10 Aug 2026 16:08:15 -0500</pubDate>

									<content:encoded><![CDATA[<p><strong>Multiple Myeloma Class Action Lawsuit: What Patients Need to Know</strong> </p>
<p><em>An informative guide for anyone affected by multiple myeloma who is thinking about&#8211; or merely curious about&#8211; signing up with a class‑action lawsuit.</em> </p>
<p>Intro</p>
<p>Multiple myeloma (MM) is a plasma‑cell malignancy that impacts roughly 34,000 new patients each year in the Uni&hellip;<span class="activity-read-more" id="activity-read-more-19662"><a href="https://angelisconsulting.com/activity/p/19662/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">968270a206d5d67eb850313470b3469d</guid>
				<title>Nymand posted an update: Understanding the Landscape: Multiple Myeloma Lawsuits, [&#133;]</title>
				<link>https://angelisconsulting.com/activity/p/19542/</link>
				<pubDate>Mon, 10 Aug 2026 15:31:39 -0500</pubDate>

									<content:encoded><![CDATA[<p>Understanding the Landscape: Multiple Myeloma Lawsuits, Allegations, and What Patients Should Know</p>
<p>Multiple myeloma (MM), a cancer of plasma cells in the bone marrow, represents roughly 1.8% of all brand-new cancer cases in the United States every year, according to the American Cancer Society. While advancements in treatment have actually&hellip;<span class="activity-read-more" id="activity-read-more-19542"><a href="https://angelisconsulting.com/activity/p/19542/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">994111bed7d7e8d37a1e95db5de007c0</guid>
				<title>Nymand posted an update: Multiple Myeloma Lawsuits: What Patients Need to Know About [&#133;]</title>
				<link>https://angelisconsulting.com/activity/p/19525/</link>
				<pubDate>Mon, 10 Aug 2026 15:25:27 -0500</pubDate>

									<content:encoded><![CDATA[<p><strong>Multiple Myeloma Lawsuits: What Patients Need to Know About Legal Options, Evidence, and Compensation</strong> </p>
<p><em>A helpful, third‑person overview of the growing body of litigation linked to drugs and direct exposures connected with multiple myeloma (MM).</em></p>
<p>Intro</p>
<p>Multiple myeloma&#8211; a cancer of plasma cells in the bone marrow&#8211; affects a&hellip;<span class="activity-read-more" id="activity-read-more-19525"><a href="https://angelisconsulting.com/activity/p/19525/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">dde6cbadf5d0afc572881e527f692c55</guid>
				<title>Nymand became a registered member</title>
				<link>https://angelisconsulting.com/activity/p/19479/</link>
				<pubDate>Mon, 10 Aug 2026 15:12:09 -0500</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>